Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in discovering and developing medicines targeting genetically determined dependencies within the chromatin regulatory system. The company utilizes its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. Its product pipeline includes small molecule inhibitors and protein degraders for the treatment of various cancers, including metastatic uveal melanoma, acute myeloid leukemia, myelodysplastic syndrome, synovial sarcoma, and other solid tumors. Additionally, Foghorn Therapeutics has research collaborations and license agreements with leading pharmaceutical companies to develop novel oncology therapeutics, driving its revenue through product development and partnerships.

Products

• Small molecule inhibitors

• Protein degraders

• Oncology therapeutics